ORIGINAL RESEARCH article
Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1665514
This article is part of the Research TopicAddressing Antimicrobial Resistance: Multimodal Strategies for Low-Resource EnvironmentsView all 4 articles
Antimicrobial effect of benzbromarone combined with colistin against multidrug-resistant bacteria
Provisionally accepted
- Shin-an International Hospital, Jiaxing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Drug-resistant respiratory pathogens in COPD patients pose a major therapeutic challenge. Colistin is a last-resort treatment for drug-resistant infections. But emerging resistance and hepatorenal toxicity limit its use, which highlights the need for combination strategies to improve its efficacy and safety. This study investigated the antibacterial effect of the combination of benzbromarone and colistin against drug-resistant pathogens associated with COPD. In this study, MIC determination experiments revealed that respiratory pathogens from COPD patients exhibited high resistance rates to several conventional antibiotics. Furthermore, the checkerboard assay showed that benzbromarone alone had no antibacterial effect but markedly lowered the MIC of colistin, with all FICI values < 0.5. Further growth curve and time kill curve analysis showed that colistin combination with benzbromarone significantly enhanced bacterial growth inhibition and exerted bactericidal activity. Additionally, the antibacterial mechanism showed that colistin combined with benzbromarone synergistically enhanced bacterial membrane damage, promoted ROS accumulation, and inhibited ATP production, thereby exerting stronger bactericidal effects. Moreover, validation using the Galleria mellonella larval infection model demonstrated that the benzbromarone-colistin combination provided effective protection against infections caused by multidrug-resistant Gram-negative bacteria, with larval survival rates reaching up to 70%, which was significantly higher than that observed with monotherapy. In conclusion, this study revealed that benzbromarone enhanced the antibacterial activity of colistin against COPD-associated drug-resistant pathogens, exhibiting a significant synergistic effect while effectively reducing the required colistin dosage. These findings provide a promising alternative approach for antimicrobial therapy in drug-resistant COPD infections and contribute to the exploration of new antibacterial applications for non-antibiotic drugs.
Keywords: COPD, Bacterial resistance, Colistin, Benzbromarone, combination therapy
Received: 14 Jul 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Wang, Li and Bao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaoqiang Bao, Shin-an International Hospital, Jiaxing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.